Abstract 3697
Background
Pancreatic neuroendocrine tumor (pNET) is rare and heterogeneous. New biomarkers are needed for better predicting the prognosis and providing individualized treatment. Versican (VCAN) plays an important role in tumorigenesis. Our previous study showed VCAN was specifically expressed in pNET tumor tissue. Therefore, we planned to investigate the role of VCAN in pNET prognosis.
Methods
Clinical and pathological data of pNET patients who underwent surgery between 2005 and 2010 were followed up and evaluated. VCAN expression was assessed by immunohistochemical (IHC) methods, and the relationship between VCAN and prognostic features of pNET was analyzed.
Results
Among 161 pNET patients, 118 (73.3%) pNET were VCAN expression positive and 43 (26.7%) VCAN expression negative. Positive expression of VCAN in pNET was significantly associated with longer disease-free survival (DFS) compared with VCAN-negative pNET (p = 0.017, HR 0.399, 95%CI 0.215-0.741). Subgroup analysis showed that VCAN-positive expression was associated with longer DFS in the G1 subgroup (p = 0.030, HR = 0.122, 95%CI: 0.013-1.180), tumor size>2cm subgroup (p = 0.030, HR = 0.427, 95%CI: 0.193-0.944) and NF-pNET subgroup (p = 0.001, HR = 0.251, 95%CI: 0.103-0.617). Multiple analysis showed that VCAN-negative expression, G2 and tumor size>2cm were independent factors for poor prognosis in pNET (p = 0.01, p < 0.001, p = 0.009, respectively).
Conclusions
Our data indicate that VCAN-positive expression may serve as an independent factor for predicting DFS prognosis in pNET. VCAN-positive expression in pNET tissues was correlated with longer DFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3905 - Loss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer
Presenter: Krittiya Korphaisarn
Session: Poster Display session 2
Resources:
Abstract
3963 - Robot-assisted natural orifice specimen extraction surgery for radical resection of colorectal cancer
Presenter: Zhengchuan Niu
Session: Poster Display session 2
Resources:
Abstract
3989 - Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III Study by the GERCOR Group
Presenter: Thierry André
Session: Poster Display session 2
Resources:
Abstract
4741 - Real world data on adjuvant chemotherapy for high-risk stage II colorectal cancer – the role of tumor side
Presenter: Camila Araujo de Carvalho
Session: Poster Display session 2
Resources:
Abstract
4973 - Oncological Outcome and Safety of Bevacizumab (BV) Therapy in Patients with Occlusive Colon Cancer and Self-Expandable Metal Stents (SEMS)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 2
Resources:
Abstract
2295 - Active chronic hepatitis B increases the risk of liver metastasis of colorectal cancer- a retrospective clinical study of 7187 consecutive cases of newly diagnosed colorectal cancer
Presenter: Lei Zhao
Session: Poster Display session 2
Resources:
Abstract
3845 - Comprehensive Evaluation of Recurrence Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation
Presenter: Wei Ye
Session: Poster Display session 2
Resources:
Abstract
1976 - BRAF-mutated colorectal metastases: what is the benefit of liver surgery? Results from a cohort of 91 patients.
Presenter: Sahir Javed
Session: Poster Display session 2
Resources:
Abstract
2688 - The smallest colorectal liver metastasis size as a prognosis factor after laparoscopic liver resection
Presenter: Baptiste Cervantes
Session: Poster Display session 2
Resources:
Abstract
4961 - Validation of GAME score risk groups in resected colorectal cancer liver metastases and the prognostic relevance of KRAS, NRAS and BRAF mutation analysis
Presenter: Berta Martin-Cullell
Session: Poster Display session 2
Resources:
Abstract